NCT00436644View on ClinicalTrials.gov

Lapatinib and Topotecan in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Did Not Respond to Cisplatin or Carboplatin

PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

March 31, 2009

Study Completion Date

November 30, 2012

Conditions
Ovarian CancerPeritoneal Cavity Cancer
Interventions
DRUG

Lapatinib

1250 mg orally days 1 -28.

DRUG

Topotecan

3.2 mg/m2 IV over 30 min in 100mL D5W (5% dextrose in water) or 0.9% NS at days 1, 8 \& 15.

Trial Locations (3)

32224

Mayo Clinic in Jacksonville, Jacksonville

55905

Mayo Clinic Cancer Center, Rochester

85254

Mayo Clinic Arizona, Scottsdale

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Mayo Clinic

OTHER